Payers, oncologists, and oncology policy experts provide their feedback on the Oncology Care Model developed by the Centers for Medicare and Medicaid Innovation, which aims to link payment to the quality of care, improve access to care, and enhance information sharing.
In February, the Centers for Medicare and Medicaid Services Innovation Center (CMMI) announced the rollout of its long-awaited Oncology Care Model (OCM)—a payment model that includes financial and performance accountability for episodes of care (EOC) with regards to chemotherapy administration to patients with cancer. The goals of the OCM are part of the Department of Health and Human Service’s initiative to link payments to quality care, improvement in care delivery, and sharing information more broadly to support better decision making. Financial incentives are based on a 6-month chemotherapy EOC, and participating practices will receive monthly care management payments for each Medicare fee-for-service beneficiary during an EOC.
OBR interviewed several stakeholders on how they received the OCM and what they think are the pros and cons of the model.